Why Oligonucleotide Therapeutics Are Moving Into Mainstream Drug Development
Oligonucleotide therapeutics have moved from a specialist field into a central part of modern drug discovery. The reason is straightforward: they give drug developers a direct way to modulate genetic information. Instead of looking for a small molecule binding pocket or engineering a large protein-based therapeutic, oligonucleotide drugs can be designed against an RNA sequence, a splice site, a disease-causing transcript or, in some cases, an RNA structure. That design logic has made the field attractive for diseases that were once considered difficult to address with conventional modalities.
The category is broad. It includes antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNA-related agents, aptamers and messenger RNA (mRNA)-based products. These are not interchangeable technologies. Each modality has its own mechanism, chemistry, delivery requirements, manufacturing challenges and clinical development logic. However, they share one important industry feature: once a platform is validated, the same design, chemistry and process-development knowledge can often be reused across multiple programs.
That platform effect is one reason the sector has attracted increasing attention from pharmaceutical companies, biotechnology startups, investors and supply-chain partners. The field is no longer defined only by rare disease programs. It now includes cardiometabolic disease, liver disease, neurology, ophthalmology, infectious disease, oncology and vaccine-related applications. Some areas are already better validated than others, but the direction is clear: oligonucleotide therapeutics are becoming an important modality class rather than a niche technology.
For companies involved in advanced intermediates, specialty building blocks, linkers, conjugation chemistry, lipid materials, analytical support and process development, this shift creates a practical question: where does demand actually emerge? It does not emerge only at the finished-drug level. It appears much earlier, in modified nucleosides, phosphoramidites, solid supports, protected monomers, ligand-linker systems, ionizable lipids, PEG-lipids, impurity standards, analytical methods and scalable purification strategies. Understanding the market therefore requires looking not only at clinical pipelines, but also at the chemistry and manufacturing infrastructure behind them.
The Main Modalities in Oligonucleotide Therapeutics
Although the industry often speaks about "small nucleic acid drugs" as a single category, the underlying modalities differ in important ways.
| Modality | Typical Mechanism | Common Development Focus | Key Technical Dependency |
|---|---|---|---|
| Antisense oligonucleotides (ASOs) | Bind target RNA to alter splicing, block translation or recruit RNase H-mediated degradation | Rare disease, neurology, metabolic disease, genetic disorders | Chemical modification, tissue exposure, nuclease stability, sequence design |
| siRNA therapeutics | Use RNA interference to silence target mRNA through the RISC pathway | Liver targets, cardiometabolic disease, metabolic disorders, emerging extrahepatic targets | Delivery platform, duplex design, stabilization chemistry, conjugation or nanoparticle formulation |
| microRNA-related therapeutics | Mimic or inhibit microRNA function to regulate gene networks | Fibrosis, oncology, cardiovascular and inflammatory disease research | Specificity, safety margin, delivery and pathway complexity |
| Aptamers | Folded oligonucleotides bind proteins or other molecular targets | Ophthalmology, diagnostics and targeted delivery research | Folding stability, target affinity, nuclease resistance and formulation |
| mRNA-based products | Deliver coding RNA so cells produce a protein antigen or therapeutic protein | Vaccines, protein replacement, cancer immunotherapy research | Lipid nanoparticle formulation, RNA quality, innate immune control and cold-chain strategy |
ASOs and siRNAs currently represent the most established small oligonucleotide therapeutic formats. ASOs are typically single-stranded and depend heavily on backbone, sugar and base modifications to improve potency, stability and distribution. siRNAs are double-stranded and depend strongly on delivery, especially GalNAc conjugation for hepatocyte targeting and lipid nanoparticles for broader nucleic acid delivery. mRNA products are larger and are usually discussed separately from small oligonucleotide drugs, but they share supply-chain themes, including modified nucleotides, lipid excipients, formulation control and analytical complexity.
This diversity has practical consequences. No single manufacturing or delivery strategy fits all modalities, so it is more useful to understand where the modalities overlap and where they diverge. ASOs and siRNAs, for example, share much of the same solid-phase synthesis chemistry but differ sharply in delivery logic, while mRNA sits closer to the LNP formulation world than to small-oligonucleotide synthesis.
What Is Driving Industry Growth?
Several forces are pushing oligonucleotide therapeutics forward at the same time.
First, the mechanism is now clinically credible. RNA interference, antisense modulation and RNA-based expression are no longer purely experimental concepts. Approved products and late-stage programs have shown that oligonucleotide drugs can produce durable pharmacology in selected tissues. This has reduced the perceived technology risk for many targets, especially in the liver and in certain locally administered indications.
Second, delivery has improved. Early oligonucleotide programs were often limited by poor tissue exposure, rapid degradation, renal clearance or unacceptable dosing requirements. Chemical stabilization, ligand conjugation, lipid nanoparticle engineering and improved formulation methods have changed the development landscape. GalNAc-siRNA conjugates, for example, have made hepatocyte-directed RNA interference more practical for many liver-expressed targets. LNP systems, meanwhile, have shown that nucleic acids can be protected, transported and released in vivo when formulation composition and process parameters are well controlled.
Third, the field benefits from platform learning. Once a company develops a reliable design and manufacturing approach for a modality, it can often apply that knowledge to adjacent targets. Sequence-specific optimization is still necessary, but many chemistry, analytics, safety and process principles remain reusable. This is especially attractive in therapeutic areas where multiple genes or transcripts are implicated.
Fourth, pharmaceutical companies increasingly view oligonucleotide platforms as strategic assets. They can complement small molecules, biologics and cell or gene therapies. They also offer a way to address genetically validated targets that may not have obvious protein-binding sites. This strategic value has contributed to licensing, collaboration and acquisition activity across the field.
Finally, the manufacturing ecosystem is becoming more sophisticated. The industry now has more experience with solid-phase oligonucleotide synthesis, modified monomer supply, high-resolution analytics, nanoparticle formulation and conjugation chemistry. That does not make development easy, but it does mean that technical problems are increasingly addressable through specialized expertise.
Delivery Platforms Shape the Market
Delivery is one of the defining constraints in oligonucleotide drug development. A highly potent sequence is not useful if it cannot reach the right tissue, cell type or intracellular compartment at a tolerable dose. This is why the market is often segmented not only by modality, but also by delivery strategy.
| Delivery Strategy | Main Strength | Common Use Case | Development Challenge |
|---|---|---|---|
| GalNAc conjugation | Efficient hepatocyte targeting through the asialoglycoprotein receptor | Liver-expressed targets, chronic subcutaneous dosing | Linker design, conjugation consistency, metabolite understanding and extrahepatic limitations |
| Lipid nanoparticles (LNPs) | Protect and package nucleic acids, support systemic delivery of larger RNA cargos | mRNA vaccines, mRNA therapeutics, gene-editing payloads and some siRNA applications | Particle size, encapsulation efficiency, lipid purity, stability and scale-up |
| Local administration | High exposure at the site of action | Eye, CNS, respiratory tract or local tissue applications | Procedure burden, distribution, local tolerability and formulation retention |
| Alternative conjugates | Potential tissue targeting beyond liver | Muscle, tumor, immune cell or CNS research | Receptor validation, linker stability, uptake and endosomal escape |
| Physical or device-assisted delivery | Can improve local tissue access | Research-stage applications in selected tissues | Translational complexity, reproducibility and patient acceptability |
GalNAc and LNP are currently the two most important delivery stories for commercial and near-commercial nucleic acid development. GalNAc is especially powerful for liver-targeted siRNA and ASO programs because it combines receptor-mediated uptake with a relatively defined conjugation format. LNP technology is broader in principle and particularly important for mRNA and other larger RNA cargos, but formulation complexity is higher.
Extrahepatic delivery remains a major opportunity and a major technical barrier. Tumor delivery, central nervous system delivery, immune cell targeting and muscle delivery all attract strong interest, but each comes with biological and manufacturing challenges. As the field expands beyond liver targets, demand will grow for new ligands, linkers, ionizable lipids, helper lipids, polymeric carriers, targeting moieties and analytical methods that can characterize complex delivery systems.
From Modality Innovation to Supply Chain Demand
The growth of oligonucleotide therapeutics creates demand across the entire development chain. Some demand is visible: drug substance manufacturing, formulation and fill-finish capacity. Other demand is less visible but equally important: specialty raw materials, impurity standards, process intermediates, analytical reference materials and small-scale custom synthesis for route exploration.
| Supply Chain Category | Examples | Why It Matters |
|---|---|---|
| Modified nucleosides and nucleotides | 2'-OMe, 2'-F, locked nucleic acid-related structures, modified bases | Improve stability, potency, immune profile and pharmacokinetic behavior |
| Phosphoramidites | Standard and modified monomers for solid-phase synthesis | Determine synthesis efficiency, impurity profile and scalability |
| Solid supports | CPG and polymeric supports with defined loading | Affect coupling efficiency, chain length control and downstream purification |
| Linkers and conjugation handles | Cleavable linkers, stable linkers, amine/azide/alkyne handles | Enable ligand attachment, metabolite tuning and platform design |
| GalNAc-related materials | GalNAc clusters, ligand-linker intermediates, conjugation precursors | Support hepatocyte-targeted siRNA and ASO development |
| Lipid materials | Ionizable lipids, helper lipids, PEG-lipids and related analogs | Define LNP potency, particle properties, tolerability and stability |
| Analytical standards | Process impurities, metabolites, reference compounds | Support method development, impurity tracking and regulatory documentation |
CHEMOS focuses on the chemistry-intensive parts of this supply chain rather than finished-drug manufacturing. This includes functional molecular building blocks, modified intermediates, ligand-linker chemistry, lipid-related materials, impurity standards and process-development support — the areas where specialized material development and custom synthesis add the most value.
This positioning is especially relevant because many oligonucleotide programs require non-standard materials. A sequence may need a modified monomer that is not available at the right scale. A GalNAc conjugate may require a specific linker architecture. An LNP formulation may require screening of ionizable lipid analogs or PEG-lipid structures. An analytical team may need an impurity standard to qualify a method. These needs appear repeatedly as programs move from discovery to preclinical development and then toward clinical manufacturing.
Manufacturing Considerations Behind the Market
Oligonucleotide manufacturing is often described as modular because solid-phase synthesis can be adapted to different sequences. That is partly true, but it can be misleading if taken too far. Each sequence, modification pattern and conjugation strategy can affect coupling efficiency, depurination, deletion sequences, phosphorothioate diastereomer profiles, residual protecting groups, aggregation, purification behavior and final analytical release.
Scale-up also changes the development problem. Conditions that work well at milligram or gram scale may not translate cleanly to larger batches. Reagent excess, solvent handling, cycle times, moisture control, support swelling, cleavage and deprotection conditions, and purification load all become more important. For siRNA duplexes, annealing and duplex purity must also be controlled. For conjugates, the consistency of ligand attachment and linker-related impurities becomes part of the critical quality discussion.
LNP manufacturing adds another layer. Particle size, polydispersity, encapsulation efficiency, lipid ratio, residual solvents, pH history, mixing conditions, sterile filtration, storage temperature and container compatibility can all influence performance. This is why LNP development is not simply a formulation recipe. It is an integrated process involving material quality, mixing technology, analytical characterization and stability strategy.
The industry opportunity therefore lies in reliability. Developers need materials that are available, well characterized and suitable for process understanding. They also need partners who can think beyond catalog supply and support route scouting, impurity identification, scale-up feasibility and documentation.
Key Technical Risks Developers Watch Closely
| Risk Area | Why It Matters | Practical Mitigation |
|---|---|---|
| Sequence-related impurities | Deletion, truncation and modification-related impurities can affect purity and potency | Optimize coupling, capping, oxidation/sulfurization and purification conditions |
| Chemical stability | Hydrolysis, oxidation or depurination can reduce product quality | Control protecting groups, storage, pH, moisture and analytical monitoring |
| Delivery performance | Uptake and tissue exposure determine pharmacology | Screen conjugates, lipids, linkers and formulation parameters early |
| Immunostimulation | Nucleic acids and delivery materials can activate innate immune pathways | Use appropriate modifications and evaluate sequence/formulation effects |
| Scale-up reproducibility | Small-batch success may not predict large-batch performance | Build process understanding before locking manufacturing conditions |
| Analytical complexity | Impurities can be structurally similar to the target product | Use orthogonal LC-MS, ion-pair methods, capillary electrophoresis and reference standards |
| Regulatory documentation | Material provenance and impurity control become more important as programs advance | Maintain specifications, CoA packages and traceable development records |
These risks are not reasons to avoid the field. They are the reason specialized chemistry and analytical support matter. In a maturing market, technical credibility becomes more valuable than broad claims. Developers want suppliers and partners who understand the practical constraints of oligonucleotide synthesis, conjugation and delivery-material development.
China, Global Pipelines and the Supply Chain Opportunity
The oligonucleotide field is global. Innovation comes from multinational pharmaceutical companies, platform biotechnology companies, academic spinouts, specialist CDMOs and material suppliers. China has become increasingly active in nucleic acid therapeutics through discovery programs, clinical development, manufacturing capacity and upstream material capabilities. This creates a more competitive landscape, but it also expands the need for reliable specialty inputs.
For global customers, supply-chain resilience is now a strategic topic. Developers want qualified alternatives for key intermediates, predictable lead times, documentation support and the ability to customize structures when standard catalog materials do not fit a program. For Chinese companies entering global development, the challenge is not only making a molecule; it is building a documentation and quality mindset that can support international collaboration.
This is where CHEMOS can communicate clearly. The company does not need to present itself as a finished-drug developer. A more useful message is that CHEMOS can support research and process-development teams with custom synthesis, functional building blocks, linker chemistry, lipid-related materials, GalNAc-related intermediates and analytical reference compounds. This is specific, believable and aligned with the way oligonucleotide programs actually progress.
What This Means for CHEMOS Customers
For customers working on oligonucleotide therapeutics, the most valuable supplier is often the one that can solve narrow chemistry problems quickly and document the solution clearly. A development team may need a modified phosphoramidite for a sequence screen, a GalNAc linker intermediate for conjugate optimization, an ionizable lipid analog for LNP formulation work or a reference standard for impurity assignment. These are not always large commercial orders at the beginning. They are technical starting points that can become strategic supply relationships if the program advances.
FAQ
What are oligonucleotide therapeutics?
Oligonucleotide therapeutics are medicines or investigational agents based on short nucleic acid sequences. They can bind RNA, modulate splicing, silence gene expression, regulate microRNA pathways, bind molecular targets or deliver coding RNA. Major categories include ASOs, siRNAs, aptamers, microRNA-related agents and mRNA-based products.
Why is delivery so important for oligonucleotide drugs?
Oligonucleotides are large, charged molecules that do not easily cross biological membranes. They can also be degraded by nucleases or cleared rapidly from circulation. Delivery technologies such as GalNAc conjugation, lipid nanoparticles and local administration strategies help determine where the molecule goes, how efficiently it enters cells and whether the dose is practical.
Why is GalNAc important in siRNA development?
GalNAc conjugation enables efficient targeting of hepatocytes through the asialoglycoprotein receptor. This has made liver-directed siRNA and some ASO programs more practical, especially for targets expressed in the liver. GalNAc is not a universal delivery solution, but it is one of the most important validated conjugation strategies in the field.
How are LNPs different from GalNAc conjugates?
GalNAc conjugates are chemically attached ligand-oligonucleotide systems designed mainly for receptor-mediated liver uptake. LNPs are nanoparticle formulations that package nucleic acid cargos with lipids. LNPs are especially important for mRNA and other larger RNA cargos, while GalNAc is especially important for hepatocyte-targeted siRNA and ASO development.
What materials are important in oligonucleotide therapeutic development?
Important materials include modified nucleosides, phosphoramidites, solid supports, linkers, GalNAc-related intermediates, ionizable lipids, PEG-lipids, helper lipids, conjugation handles and analytical reference standards. The exact material set depends on the modality, sequence, delivery strategy and development stage.
What supply-chain challenges do oligonucleotide developers face?
Common challenges include long lead times for specialty monomers, limited access to custom linkers or lipid analogs, impurity-standard availability, scale-up reproducibility and documentation quality. As programs advance, material traceability and analytical support become increasingly important.
How can CHEMOS support oligonucleotide-related programs?
CHEMOS can support research and process-development teams through custom synthesis, functional molecular building blocks, modified intermediates, linker chemistry, GalNAc-related materials, lipid-related materials and analytical reference compounds. The goal is to support technical development needs rather than make unsupported therapeutic claims.
Notice
This article is for research and technical information purposes only. It is not intended as medical, regulatory or legal advice. Materials and technologies discussed should be used according to applicable research-use, safety and regulatory requirements.
References and Further Reading
- Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nature Reviews Drug Discovery, 2019. https://doi.org/10.1038/s41573-019-0017-4
- Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery, 2020. https://doi.org/10.1038/s41573-020-0075-7
- Crooke ST, Baker BF, Crooke RM, Liang XH. Antisense technology: an overview and prospectus. Nature Reviews Drug Discovery, 2021. https://doi.org/10.1038/s41573-021-00162-z
- Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. The current landscape of nucleic acid therapeutics. Nature Nanotechnology, 2021. https://doi.org/10.1038/s41565-021-00898-0
- Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 2021. https://doi.org/10.1038/s41578-021-00358-0
- Nair JK, Willoughby JLS, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. Journal of the American Chemical Society, 2014. https://doi.org/10.1021/ja505986a
- Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Therapeutics, 2018. https://doi.org/10.1089/nat.2018.0736
- FDA. Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry, 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry
- ICH. Quality Guidelines. https://www.ich.org/page/quality-guidelines